Recent Advances in the Development of Broad-Spectrum Antiprotozoal Agents

(E-pub Ahead of Print)

Author(s): Antonio Moreno-Herrera, Sandra Cortez-Maya, Virgilio Bocanegra-Garcia, Bimal Krishna Banik, Gildardo Rivera*.

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer


Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low- and high-income countries and their pharmacological treatment is limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidazole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.

Keywords: Antiprotozoal, drugs, Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Giardia lamblia, Trichomonas vaginalis, Plasmodium spp., Entamoeba histolytica.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867327666200303170000
Price: $95

Article Metrics

PDF: 1